Evidence map›Paper›PMID 23824743›Full record

ArticleCancer research2013

Chemopreventive activity of plant flavonoid isorhamnetin in colorectal cancer is mediated by oncogenic Src and β-catenin.

Shakir M Saud, Matthew R Young, Yava L Jones-Hall, Lilia Ileva, Moses O Evbuomwan, Jennifer Wise, Nancy H Colburn, Young S Kim, Gerd Bobe

Open access · greenAbstract read
In one paragraph

Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
31.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Oncometabolite 5-IPNature chemical biology · 2026
    Article
  3. Review
  4. Review
  5. Molecular Mechanisms of Phytochemicals from Chaga Mushroom (International journal of molecular sciences · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Total Flavonoids inInternational journal of molecular sciences · 2023
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Potential ofMolecules (Basel, Switzerland) · 2022
    Review
  19. Current research in food science · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Shakir M SaudNutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Corvallis, Oregon, USA.
Matthew R Young
Yava L Jones-Hall
Lilia Ileva
Moses O Evbuomwan
Jennifer Wise
Nancy H Colburn
Young S Kim
Gerd Bobe
Linus (Norway) · NOCancer Institute (WIA) · INScience Applications International Corporation (United States) · USCenter for Cancer Research · USNational Cancer Institute · US

Funding

Identification of Biomarkers for Response to Chemoprevention of Colon CancerZIABC011159 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI COLBURN, NANCY H. · 2009 to 2013
$1.3M
Intramural NIH HHS Z99 CA999999NCI NIH HHS Y99 CA999999
6 · The paper itself

Abstract

Analysis of the Polyp Prevention Trial showed an association between an isorhamnetin-rich diet and a reduced risk of advanced adenoma recurrence; however, the mechanism behind the chemoprotective effects of isorhamnetin remains unclear. Here, we show that isorhamnetin prevents colorectal tumorigenesis of FVB/N mice treated with the chemical carcinogen azoxymethane and subsequently exposed to colonic irritant dextran sodium sulfate (DSS). Dietary isorhamnetin decreased mortality, tumor number, and tumor burden by 62%, 35%, and 59%, respectively. MRI, histopathology, and immunohistochemical analysis revealed that dietary isorhamnetin resolved the DSS-induced inflammatory response faster than the control diet. Isorhamnetin inhibited AOM/DSS-induced oncogenic c-Src activation and β-catenin nuclear translocation, while promoting the expression of C-terminal Src kinase (CSK), a negative regulator of Src family of tyrosine kinases. Similarly, in HT-29 colon cancer cells, isorhamnetin inhibited oncogenic Src activity and β-catenin nuclear translocation by inducing expression of csk, as verified by RNA interference knockdown of csk. Our observations suggest the chemoprotective effects of isorhamnetin in colon cancer are linked to its anti-inflammatory activities and its inhibition of oncogenic Src activity and consequential loss of nuclear β-catenin, activities that are dependent on CSK expression.

Indexed as

PhytotherapyAnimalsApoptosisAzoxymethanebeta CateninBlotting, WesternCell NucleusCell ProliferationColorectal NeoplasmsCSK Tyrosine-Protein KinaseDextran SulfateHumansImmunoenzyme TechniquesMaleMicePlant Extracts3-methylquercetinAzoxymethanebeta CateninCSK protein, humanCSK Tyrosine-Protein KinaseDextran SulfatePlant ExtractsQuercetinRNA, MessengerRNA, Small Interferingsrc-Family Kinases

Identifiers

PMID23824743
PMCPMC3870026
OpenAlexW2124701250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.